2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Hereditary Sensory and Autonomic Neuropathies
3
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced BRAF-mutant Cancers
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
PX-866
×
Clear all
NCT00726583
2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1
Completed
90 enrolled